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ABSTRACT
Objective: To identify a cost-saving subset of criteria for the
use of tiotropium at a Veterans Affairs Medical Center based
on a cost-effectiveness analysis with ipratropium as the
comparator.
Methods: Retrospective analysis of electronic medical
records for the calendar year 2004 was conducted. The
sample was drawn from a population at the Baltimore Vet-
erans Affairs Medical Center that had a conﬁrmed diagnosis
of chronic obstructive pulmonary disease (COPD) and had
ﬁlled prescriptions for ipratropium. The tiotropium sample
was based on a modeled cohort of COPD patients who had
received tiotropium. The analysis was conducted from the
perspective of the Veterans Affairs Health Care System. The
outcome was the incremental cost-effectiveness of tiotropium
versus ipratropium.
Results: The incremental cost-effectiveness ratio (ICER)
was $2360 per avoided exacerbation. Tiotropium cost-
effectiveness increased with COPD severity and was cost-
saving in patients with very severe disease (ICER = $-1818)
and in patients with a previous COPD-related hospitalization
(ICER = $-4472). The ICERwasmost sensitive to the relative
effectiveness and price of tiotropium. Results identiﬁed the
levels of treatment effectiveness and price beyond which
tiotropiumwould become cost-saving relative to ipratropium.
Conclusions: The results support the existing Veterans
Affairs practice of offering tiotropium to patients with
COPD-related hospitalizations. Periodic review of the effec-
tiveness data to determine whether tiotropium would be
cost-saving in patients with very severe COPD is suggested.
Cost-effectiveness analyses that identify practical criteria-for-
use should become an integral part of the formulary process.
Keywords: chronic obstructive pulmonary disease, cost-
effectiveness, formulary decision-making, tiotropium,
veterans population.
Introduction
From its humble beginnings as a simple list of pre-
ferred drugs, over time the modern formulary has
become a complex management process designed to
promote cost-effective drug utilization. The formulary
review process typically begins with a scientiﬁc evalu-
ation that seeks to assess whether a new drug offers
measurable and clinically meaningful risk–beneﬁt
advantages over alternative agents already on formu-
lary. Once this initial review is satisﬁed, the next step
is to develop criteria-for-use (CFU) under which the
beneﬁts of the new drug best justify its costs. The
economic analysis is straightforward under certain sce-
narios such as 1) when the new treatment offers dra-
matically greater efﬁcacy; 2) when increased efﬁcacy is
provided at no additional cost relative to existing treat-
ment; or 3) when the new treatment generates obvious
savings. Nevertheless, when treatment beneﬁts are
small and apply differentially to various patient sub-
populations, then more detailed cost-effectiveness
analysis (CEA), budget impact analysis (BIA), and sen-
sitivity analyses must be conducted if economic
considerations are to be rationally incorporated into
the CFU.
Cost-effectiveness analyses may offer additional
value if they are developed with the complementary
intent of helping decision-makers arrive at better
CFU. This formulary decision-support paradigm
would incorporate the following desirable CEA appli-
cations: 1) a focus on developing practical CFU (i.e.,
those that rely on populations, clinical conditions, and
outcomes that can be readily identiﬁed by typical prac-
titioners); 2) the use of assumptions that reﬂect real-
world health-care utilization, as these often differ from
drug use and health services within clinical trials; and
3) a sensitivity analysis that identiﬁes circumstances
under which CFU would need to be revisited. In this
work, we maintain that a series of CEA applications
that follow the above blueprint can provide infor-
mation that enhances CFU. This approach also is
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consistent with the International Society for Pharma-
coeconomics and Outcomes Research BIA Task Force
recommendations [1].
In order to examine the complementary role that a
CEA can have on CFU, we conducted a proof-of-
concept CEA from the perspective of the Veterans
Affairs (VA) Health Care System, an integrated health-
care system that provided pharmaceutical beneﬁts to
about 4.3 million veterans in ﬁscal year 2006, at a cost
in excess of $3.4 billion for outpatient drug therapies
alone. We selected the VA because its ﬁxed global
budget and state-of-the-art formulary process combine
to create carefully balanced, cost-conscious CFU that
ultimately could be used as a comparator to the CFU
developed herein. We selected tiotropium, an anticho-
linergic bronchodilator, as an example of a drug whose
CFU may beneﬁt from a CEA. Compared to the four-
times daily dosing of ipratropium, a bronchodilator
already on formulary, tiotropium is inhaled once a day
[2,3]. Widespread use of this more convenient drug
would entail new annual drug expenditures in excess
of $90 million; thus, existing VA formulary guidelines
have limited the use of tiotropium to patients with
chronic obstructive pulmonary disease (COPD) who
are on a drug regimen that includes a combination of
short-acting beta-adrenergic (albuterol) and anticho-
linergic (ipratropium) agents as well as a long-acting
beta-agonist (LABA), yet still suffer from disabling
symptoms. Published evidence indicates that a long-
acting inhaled anticholinergic (tiotropium) is more
effective than a short-acting inhaled anticholinergic
(ipratropium) at reducing the occurrence of disabling
symptoms like exacerbations [4].
The purpose of this analysis was not to completely
delineate how tiotropium should be utilized at the VA.
Rather, we coupled traditional economic analyses with
real-world observations about disease severity and
health-care resource utilization to develop a readily
identiﬁable subset of CFU that formulary decision-
makers could agree to implement: speciﬁcally, those
CFU predicted to be cost-saving. We then considered
to what extent the information from this CEA could
improve on the CFU currently in use at the VA, with
the ultimate goal of advancing the formulary selection
process.
Methods
This retrospective study used electronic medical
records to compare health utilization data from an
actual sample of patients receiving ipratropium to that
of a modeled (hypothetical) population of patients
receiving tiotropium. We chose to compare tiotropium
to ipratropium because the soon-to-be released
VA/Department of Defense guidelines mandate the
discontinuation of ipratropium on introduction of
tiotropium; they do not require stopping the LABA.
We conducted the study at the Veterans Affairs
Maryland Health Care System, which provides com-
prehensive health-care services to veterans living in
Maryland. Given our narrow goal of identifying a
subset of CFU that VA decision-makers could agree on,
we limited our analysis to costs and beneﬁts that
would accrue to the VA. Thus, our results do not
account for how the tiotropium/ipratropium choice
impacts the time, resource, and compliance costs borne
by the patients, their non-VA caregivers, or society.
The study was approved by the University of Mary-
land Baltimore Institutional Review Board.
Ipratropium Patient Sample
Inclusion criteria used to deﬁne the ipratropium cohort
were: 1) a ﬁlled prescription for ipratropium (ipratro-
pium or albuterol/ipratropium oral inhalers and ipra-
tropium inhaler solution) anytime between January 1,
2004 and December 31, 2004; and 2) pulmonary func-
tion tests (PFTs) conducted at any time before January
1, 2005. The PFTs included observed and predicted
postbronchodilator values for forced expiratory
volume in 1 second (FEV1) and for the ratio of FEV1 to
forced vital capacity. The most recent PFT results were
combined with the Global Initiative for Chronic
Obstructive Lung Disease (GOLD) criteria [5] to diag-
nose and categorize COPD patients according to
disease severity.
Cost measures were calculated by cost center. Pre-
scription costs were calculated based on the number of
drug units dispensed per month, multiplied by the
monthly unit price. The total drug cost per patient per
unit of time was calculated by summing the individual
prescription costs. Emergency room (ER) visits and
hospitalizations that were related to a COPD exacer-
bation and potentially preventable by tiotropium were
identiﬁed by a structured review of the computerized
patient record system (CPRS) entries. CPRS records
surrounding the 1291 ER visits and 638 hospital
admissions undergone by the ipratropium COPD
population during the study period were examined. We
identiﬁed a COPD exacerbation (event) as that subset
of exacerbations that led to an ER visit or to a hospi-
talization at the VA Medical Center. A COPD exacer-
bation event was deﬁned as follows: an increase in
sputum production, or a change in sputum quality, or
an increase in shortness of breath compared to base-
line, and symptoms not attributable to running out of
bronchodilators, and symptoms not clearly due to a
condition other than COPD. The record review con-
sisted of two steps. First, all ER and initial admission
notes and hospital discharge summaries to identify
those events that satisﬁed the ﬁrst four clauses of
our deﬁnition of COPD exacerbation were reviewed.
These potential events, as well as a 10% sample of the
nonevents, were then reviewed by a pulmonologist
(SD) who validated the ﬁrst four clauses, and then
Cost-Effectiveness Analysis of Tiotropium 981
evaluated the last clause of the event deﬁnition. Con-
ditions allowed to supersede COPD as the main cause
of the respiratory exacerbation were limited to the
following: new chest-x-ray-inﬁltrates suggestive of a
pneumonia; pneumothorax; enlarging pleural effu-
sion(s); new anemia (hematocrit decline of 9 since
the last measurement); new metabolic acidosis with
respiratory compensation; bronchospasm due to an
acute allergic reaction; and congestive heart failure,
suggested by two or more of the following: typical and
rapidly (24 hours) reversible chest x-ray pattern,
rapid (24 hours) response to diuretics, left ventricu-
lar ejection fraction less than 40% by echocardio-
graphy or multiple-gated acquisition nuclear scan,
acute myocardial infarction, severe arrhythmias, docu-
mented positive ﬂuid balance of more than 3.5 L in
24 hours. COPD exacerbations where contributions
from diseases other than COPD were suspected but
which did not exhibit the speciﬁc features outlined
above, were attributed to COPD. Although every
effort was made to correctly identify an exacerbation
related to COPD, we did not identify, for each hospi-
talization or ER visit, the proportion of resources that
was devoted solely to the treatment of a COPD
exacerbation.
Tiotropium Modeled Patient Sample
The tiotropium patient sample was modeled after the
above ipratropium population, except for the follow-
ing changes to their health resource utilization: First, in
terms of prescription costs, the modeled tiotropium
patients were assumed to be 50%more compliant with
their individual reﬁll schedule (number of actual reﬁlls/
number of allowed reﬁlls) than patients on ipratro-
pium [6]. Monthly quantity units were not available
for nebulized solutions; no difference in compliance
was assumed for these medications. Second, in terms
of ER visits and hospitalizations related to a COPD
exacerbation, exacerbation-related hospitalizations/
patient-year were assumed to be 28% lower for the
modeled patients on tiotropium and ER visits were
assumed to be 20% lower, based on the study by
Niewoehner et al. [7], which directly compared tiotro-
pium to placebo in a similar (veterans) population.
Unit Cost Assumptions
The unit cost for a hospitalization was set at $1619 per
day based on national VA estimates [8]. ER costs,
based on statewide estimates, were assumed at
$277.04 per visit [9]. State estimates for the emergency
department were preferred to VA estimates given that
veterans needing emergency care are likely to be trans-
ported to the nearest ER (often not a VA medical
center); charges are then reimbursed by the VA.
Average costs for a 30-day prescription at the VA
center during the study period were $20 for ipratro-
pium and $68.27 for tiotropium.
Discounting
The period of analysis covered one calendar year there-
fore, no discounting was applied to costs or effects.
Incremental Cost-Effectiveness Ratio (ICER)
We identiﬁed two outcome measures (OMs) that rep-
resented cost components for the VA and that are
associated with serious health risk for COPD patients
[10]: avoided COPD-related VA hospitalization
(Hosp) and the sum of avoided VA hospitalizations
and ER visits due to a COPD exacerbation (HospER).
Other studies in COPD and asthma populations have
used similar OMs [11–14]. For each OM,
OM  {Hosp, HospER}, the ICEROM is deﬁned in
Equation 1:
ICER
Costs Costs
OM OM
OM
tiotropium ipratropium
tiotropium ipra
=
−
− tropium
(1)
We calculated ICERHospER and ICERHosp for the full
sample population and for speciﬁc subpopulations of
interest that could provide a practical basis for CFU: 1)
COPD severity stages; 2) at least one COPD-related
hospitalization in the last year; and 3) nonhospitalized
patients with one, two, or more than two COPD-
related ER visits in the last year.
Sensitivity Analyses
The uncertainty surrounding the ICER for the full
sample was assessed using one-way sensitivity analyses
and bootstrapped 95% conﬁdence intervals (based on
1000 resamples). A tornado diagram was used to
present the results of the one-way sensitivity analyses
and a cloud diagram was used to present the results of
the bootstrapping exercise for the full sample and the
hospitalized subsample. The assumptions regarding
exacerbation-related hospital and ER visits, unit cost
of a hospitalization, unit cost of an ER visit, unit drug
costs, and compliance rates were tested by varying the
values and examining the impact of changes on the
ICER. Unit costs were varied by 20% from the base-
case values for the sensitivity analysis. The relative
effect of tiotropium on exacerbation-related hospital
(ER) admissions was varied from 0.2 to 0.5 (0.1–0.4),
to include the range of values found in the literature.
Compliance to tiotropium treatment was varied from
0 (no difference from compliance to ipratropium) to
0.8 in the sensitivity analysis.
Additional sensitivity analyses on the parameters
exerting the strongest inﬂuence on the ICER (as iden-
tiﬁed by the tornado diagram) were conducted for each
disease severity subgroup to determine the value of the
parameter at which tiotropium became cost-saving
relative to ipratropium. A probabilistic sensitivity
982 Onukwugha et al.
analysis also was conducted based on 1000 draws to
determine the effect of uncertainty in the tiotropium
hospital effectiveness parameter on the ICER. A left-
skewed beta distribution with left and right parameters
equal to 13 and 5, respectively, was assumed for the
tiotropium hospital effect parameter. The parameter
values reﬂected a conservative assumption regarding
the effectiveness of tiotropium relative to ipratropium
with respect to reductions in hospital admissions. The
left skewness resulted in more draws from higher
values of the tiotropium hospital effect adjustment,
where higher values of the parameter indicated a
smaller positive beneﬁt relative to ipratropium.
Results
Main Results
Of 2927 ipratropium patients, 862 had PFTs per-
formed at the VA. Of those, 160 were excluded
because their PFTs either did not show evidence of
airﬂow obstruction (n = 145) or were uninterpretable
(n = 15). The ﬁnal sample contained 702 patients who
had demonstrable COPD as speciﬁed by the GOLD
criteria. Selected characteristics of the study popula-
tion are presented in Table 1 for the full sample, and by
disease severity group. COPD patients on ipratropium
were older (mean age = 69 years) and male (98% of
sample); 20% were African American, and almost
40% were current smokers. As expected, the use of
home oxygen therapy increased and body mass index
decreased with COPD severity (P-values < 0.0001).
The majority of hospitalizations (372 out of 462) and
ER visits (668 out of 879) were for reasons completely
unrelated to respiratory complaints (e.g., diabetic foot
ulcer, cataract surgery, etc.). Six respiratory decompen-
sations were attributed to diseases other than COPD:
four were due to pneumonia, one due to a new anemia,
and one due to renal failure and metabolic acidosis.
Eighty-four hospitalizations (18%) and 211 ER visits
(24%) were related to COPD exacerbations. Of those,
nine hospitalizations (11%) and 40 ER visits (19%)
did not ﬁt our deﬁnition of events potentially prevent-
able by tiotropium, because they were the direct result
of the patient’s failure to obtain timely reﬁlls for their
bronchodilators, and were thus excluded from the ﬁnal
analysis. With the exception of a high ER visit rate in
patients with mild COPD, both hospitalization and ER
visit rates increased with disease severity. The median
length-of-stay (LOS) per hospitalization was 3 to
4 days for all severity subgroups, except for patients
with very severe COPD whose median LOS was
6.25 days.
Table 2 presents the ICERHospER estimates for the
entire COPD study population, for each COPD sever-
ity subpopulations, as well as for subgroups with
tiotropium-preventable hospitalization or ER visits.
Estimates for the ICERHosp were uniformly higher than
ICERHospER in absolute value across all groups (not
presented; results are available from the authors on
request). The value for ICERHospER was negative for
patients with at least one COPD-related hospitaliza-
tion and for patients with very severe COPD. These
Table 1 Characteristics of ipratropium and tiotropium patients
Characteristics
Overall sample
(n = 702)
Mild
(n = 53)
Moderate
(n = 291)
Severe
(n = 280)
Very severe
(n = 78)
Ipratropium patients
Age, mean (SD) 68.9 (10.7) 71.9 (11.6) 68.9 (11.3) 69 (10.2) 66 (8.5)
Male, n (%) 685 (98) 53 (100) 282 (97) 273 (98) 77 (99)
Black, n (%) 146 (20) 5 (9) 60 (21) 69 (25) 13 (17)
Smoker, n (%) 280 (40) 18 (34) 116 (40) 114 (41) 31 (40)
Home oxygen, n (%) 116 (17) 5 (9) 29 (10) 51 (18) 30 (38)
Body mass index, mean (SD) 27.33 (6.6) 26.5 (5.5) 28.3 (6.5) 27.2 (6.9) 24.5 (5.7)
% FEV1/FVC, mean (SD) 50 (11.35) 62.53 (5.27) 55.05 (8.28) 46.11 (10.16) 36.47 (8.8)
% predicted FEV1, mean (SD) 51.26 (18.84) 89.74 (12.14) 62.43 (8.62) 40.05 (5.67) 23.69 (4.36)
Median length of hospital stay (day) 4 3.75 3 3.75 6.25
ER visits, mean/year (SD) 0.30 (1.28) 0.32 (1.55) 0.16 (0.47) 0.41 (1.74) 0.44 (1.19)
Hospitalization, mean/year (SD) 0.12 (0.47) 0.06 (0.3) 0.07 (0.31) 0.16 (0.55) 0.21 (0.69)
Tiotropium patients
ER visits, mean/year (SD) 0.24 (1.03) 0.26 (1.24) 0.13 (0.38) 0.33 (1.39) 0.35 (0.95)
Hospitalization, mean/year (SD) 0.09 (0.34) 0.04 (0.22) 0.05 (0.22) 0.11 (0.39) 0.15 (0.5)
FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity.
Table 2 Incremental cost-effectiveness ratio (ICER)
COPD subpopulations ICERHospER
Bootstrapped bias-corrected
mean (95% conﬁdence
interval)
Full sample 2,360 2,280 (284 to 4276)
Mild 4,691 2,349 (-12,695 to 17,392)
Moderate 5,559 5,314 (2,106 to 8,522)
Severe 2,073 1,959 (-54 to 3972)
Very severe -1,818 -2,355 (-9,790 to 5,079)
Hospitalized -4,472 -4,430 (-6,747 to -2,112)
Not hospitalized
1 ER visit 1,271 1,259 (891 to 1626)
2 ER visits 684 672 (348 to 996)
>2 ER visits 454 434 (14 to 859)
COPD, chronic obstructive pulmonary disease; ER, emergency room.
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negative ICER values indicate that tiotropium was
cost-saving, i.e., costs were higher among patients who
remained on ipratropium.
Sensitivity Analyses
The bootstrapped replicates (Fig. 1) indicated that
tiotropium was not cost-saving for the full sample but
was cost-saving for the hospitalized subsample. The
ICER based on 1000 draws was $2420 per avoided
exacerbation in the full sample. The majority of repli-
cates for the full sample were in the quadrant where
tiotropium is more effective and more costly, while all
the replicates for the hospitalized subsample were in
the quadrant where tiotropium is dominant (more
effective and less costly). Probabilistic sensitivity analy-
ses on the hospital effect adjustment based on a left-
skewed probability distribution also suggested that
tiotropium was unlikely to be cost-saving in the full
sample.
To identify plausible alternative scenarios under
which the use of tiotropium would either become or
cease to be cost-saving, a series of additional sensitivity
analyses were performed. First, the impact of varying
the model parameters on ICERHospER for the full COPD
population was considered. The results (Fig. 2) indi-
cated that the two parameters exerting the strongest
inﬂuence on ICERHospER were: 1) the effectiveness of
tiotropium relative to ipratropium based on hospital-
izations; and 2) the cost of tiotropium. These ﬁrst two
parameters may be at risk for signiﬁcant changes in the
future, as new data about the relative effectiveness of
tiotropium become available and/or drug pricing ﬂuc-
tuates. In a second step, the impact of varying these
two dominant parameters on ICERHospER in different
COPD subpopulations was evaluated. Figure 3
illustrates how, for each COPD severity subgroup,
ICERHospER decreased and thus became more favorable
when tiotropium effectiveness increased and its price
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decreased. The point at which each curve crosses the
x-axis (ICERHospER = 0) (Table 3) identiﬁes the effec-
tiveness and price beyond which tiotropium utilization
becomes cost-saving relative to ipratropium.
Discussion
Summary of Results
We performed this proof-of-concept CEA to determine
how economic tools could couple with clinical obser-
vations to better support the formulary process.
Starting from a real-world sample of veterans on ipra-
tropium, we identiﬁed a population of actual patients
and deﬁned a population of modeled patients for
whom inhaled anticholinergics were indicated. The
inclusion criteria used to deﬁne the actual sample differ
systematically from those encountered in clinical trials,
which typically exclude patients with mild COPD, sig-
niﬁcant comorbidities (e.g., congestive heart failure or
arrhythmias), and active prescriptions for supplemen-
tal home oxygen therapy [7,15,16]. Although it may
be appropriate to exclude patients with confounding
comorbidities for assessing drug efﬁcacy [10], we rea-
soned that the selection of a “real-world” sample
of patients for whom the drug treatment would be
indicated would enhance the value of a CEA aimed at
informing a formulary decision-making process.
The analysis suggested that the VA could realize
marked savings if current CFU were modiﬁed such that
tiotropium use in patients with very severe COPD and
in patients with at least one COPD-related hospitaliza-
tion that was not due to logistical difﬁculties obtaining
medications was recommended. Within each of the
COPD severity subpopulations, sensitivity analyses
estimated the marginal effectiveness and price points at
which tiotropium use would save costs relative to ipra-
tropium. It is important to note that tiotropium is
unlikely to be judged cost-effective in patients with
mild to moderate disease, for whom it costs more than
$4000 to avoid an exacerbation resulting in an ER visit
or hospitalization. The differences in ICERHospER across
disease severity groups showed a general trend toward
cost-savings as disease severity increased; however,
these differences were not statistically signiﬁcant at the
5% level based on the bootstrapped 95% conﬁdence
intervals. The lack of statistical signiﬁcance across the
severity subgroups was likely due to insufﬁcient power
to detect the effect rather than due to a lack of an
effect. On the other hand, the difference in ICERHospER
between the hospitalized subsample and the subsample
of patients admitted to the ER was statistically signiﬁ-
cant at the 5% level, indicating that tiotropium was
cost-saving in the hospitalized subsample but not so in
the ER subsample.
Even if they could be adapted to a VA population
and cost structure, some of the beneﬁts considered in
previous CEAs [13,17,18] that have compared tiotro-
pium to ipratropium would offer limited formulary
decision-support. First, some of the beneﬁts that were
evaluated are of unclear clinical signiﬁcance (e.g., an
increase in “trough” FEV1) while others (e.g., dyspnea)
are subjective and rarely measured outside of a
research environment. Such beneﬁts are neither condu-
cive to consensus building nor likely to assist in build-
ing practical CFU. Second, the ICERs for the more
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Figure 3 ICERHospER as a function of the effectiveness (left panel) and the cost (right panel) of tiotropium in chronic obstructive pulmonary disease patients
with different disease severity. ICER, incremental cost-effectiveness ratio.
Table 3 Cost-saving threshold (ICER = 0) for tiotropium hos-
pital beneﬁt and tiotropium drug cost
COPD severity Relative effectiveness Drug cost ($/month)
Mild n/a 25.50
Moderate 0.107 32.61
Severe 0.545 47.58
Very severe 0.795 87.84
COPD, chronic obstructive pulmonary disease; ICER, incremental cost-effectiveness
ratio.
Cost-Effectiveness Analysis of Tiotropium 985
concrete beneﬁts (e.g., avoided exacerbations, hospi-
talizations) were evaluated only for the full study
population, where they were all found to have positive
values. Because there is no recognized threshold below
which a positive ICER becomes “cost-effective,” the
CEA results are not sufﬁcient to affect a decision to
commit the substantial resources needed to offer
tiotropium to all COPD patients. In contrast, this
study targets drug effects that subsidize drug acquisi-
tion costs and takes advantage of the possibility that
those effects may preferentially accrue to clinically rec-
ognizable COPD subgroups. The study results not only
highlight speciﬁc instances where drug use may create
savings, but also enable decision-makers to better con-
sider the economics of expanding the use of tiotropium
to less cost-effective subpopulations.
Implication for CFUs
The maintained hypothesis that a purposefully built
CEA can improve formulary guidance can be exam-
ined by evaluating the potential impact of our ﬁndings
on VA’s current CFU. The VA currently reserves tiotro-
pium use to patients with at least moderately severe
COPD who, despite being on ipratropium, were hos-
pitalized or had two ER visits because of exacerbations
in the past year. Our ﬁndings back VA’s requirement
for a PFT-proven COPD diagnosis: 17% of our already
select minority of ipratropium patients with PFTs did
not have COPD. Our results also conﬁrm the com-
monsense of targeting tiotropium to patients hospital-
ized because of a COPD exacerbation, but would add
two further requirements: 1) the need to identify
COPD-related hospitalizations or ER visits that occur
because a patient has failed to obtain reﬁlls in time for
uninterrupted therapy as these patients are expected to
gain more from education about the reﬁll process than
from switching to a more expensive drug; and 2) the
need to stay abreast of new information on the relative
effectiveness of tiotropium especially when the news
favors tiotropium. Increases in relative effectiveness
may mean that additional cost-savings are possible
from switching patients with severe or very severe
COPD to tiotropium preemptively, rather than supply-
ing the drug only on request. Aside from the potential
cost-savings, such an active drug switch would be
expected to prevent additional high-risk exacerba-
tions. With COPD patients who visited the ER twice or
more for exacerbations but who were not admitted, as
well as for all other conditions with positive ICER
estimates, the decision to offer tiotropium remains sub-
jective and ultimately depends on willingness and
ability to pay.
The purpose of the graphs shown in Figure 3 is not
to present absolute thresholds for drug utilization, but
rather to provide an example of the type of analysis
that can be useful to decision-makers concerned
about when and how to combine new information for
a drug with existing information on the drug’s cost-
effectiveness. In this study, the sensitivity analyses
help anticipate speciﬁc conditions that could shape
future CFU. In one example, the VA could potentially
save costs by converting all existing patients with
severe COPD to tiotropium when monthly average
tiotropium acquisition costs drop below $48 per
patient. In another example, the VA could prospec-
tively measure the dominant ﬁnancial beneﬁt of
switching patients from ipratropium to tiotropium
(i.e., the reduction in hospitalization rate), and could
use this empiric value to adjust its CFU and/or to
negotiate better prices with the drug manufacturer.
Overall, the signiﬁcance of the changes that our study
could bring to existing and future CFU supports our
hypothesis that CEAs can provide meaningful formu-
lary decision-support.
Limitations
This CEA has several limitations. First, it was per-
formed from the VA perspective and thus excluded
disease-related costs incurred by other payers. With
estimates of patients who use both VA and Medicare
services ranging from 10% to 68% [19], it is quite
possible that different cost-saving niches would have
been uncovered had the study been conducted from a
societal or multiple-payer point of view. Second, our
study population included only veterans on ipratro-
pium who had PFTs. VA spirometry inclusion criteria
eliminated most of the patients on ipratropium, a
testing pattern that may not be representative of other
VA hospitals. The performance of PFTs may be asso-
ciated with a subset of patients with worse symptoma-
tology and/or higher COPD exacerbation rates. In
addition, we did not exclude comorbidities that could
have contributed to the exacerbation of respiratory
symptoms and to added hospitalization costs.
Together, these factors could have led to an overesti-
mation of the cost-effectiveness of tiotropium relative
to ipratropium. Third, the CEA reﬂects double-
counting due to the inclusion of the number of exac-
erbations in the numerator and denominator of the
cost-effectiveness ratio. This artifact of CEAs that
report “cost per event avoided” has the potential to
bias the cost-effectiveness ratio in favor of the more
effective drug. In the current study, this would bias in
favor of tiotropium because tiotropium has been
shown to be more effective than ipratropium at reduc-
ing exacerbations. Other CEA studies in airway dis-
eases have used a similar effectiveness measure [11–14]
and there is no apparent consensus in the literature
regarding the extent to which double-counting is a
problem or regarding alternate methods to consider
similar effects in a CEA. Fourth, the drug effect adjust-
ments used were based on the results from a clinical
trial comparing tiotropium to placebo. While the clini-
cal trial was conducted in a VA population, the com-
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parator is placebo and not ipratropium; therefore, the
relative effectiveness used in the present study may be
a biased estimate of the true relative effectiveness
of tiotropium relative to ipratropium. Depending on
the relative effectiveness of placebo to ipratropium
in preventing hospital admissions and ER visits in a
real-world cohort of COPD patients, the bias will
either be positive or negative. A clinical trial reported
by Vincken et al. [16] compared tiotropium to iprat-
ropium, and reported a 38% decrease in hospital
admissions, compared to the 28% decrease used in the
current study. The study by Niewoehner et al. [7] was
the preferred source of efﬁcacy parameters because the
characteristics of their VA study population would
better compare to the current study population in
terms of the age, sex, and race distribution. We were
also unable to ﬁnd reliable estimates of relative effect
differences across the four disease severity groups
investigated in our study. The trial reported in Niewoe-
hner et al.’s [7] study provides evidence of statistically
signiﬁcant effect differences in favor of tiotropium for
one of the three disease severity groups in their study.
Additional studies based on tiotropium utilization
data in a real-world COPD population will provide
more information on an important source of treatment
heterogeneity and its potential impact on the cost-
effectiveness of tiotropium.
Practical Implications of This Analysis
The current analysis estimates the cost-effectiveness of
tiotropium versus ipratropium in the absence of actual
utilization data on tiotropium for the study population
of interest. In many instances, cost-effectiveness data
are not available at the time that the formulary deci-
sion is made. Even when cost-effectiveness information
is available for a drug, the information usually will be
based on study populations that differ substantially
from the population of interest, and decision-makers
are left to infer the degree to which published effects
will be experienced in the population of interest. The
approach taken in the current study provides a more
tailored analysis, because the control group is drawn
from the study population of interest and subgroups
relevant to determining criteria for use are identiﬁed
using criteria that are readily implemented in the
current hospital system. For future analyses, we rec-
ommend conducting a CEA using actual tiotropium
utilization data and comparing the implications for
the eventual formulary decision of this fully tailored
approach, the partly tailored approach adopted in the
current study, and the utilization of results from exter-
nal studies. This type of comparison would provide
information on the extent to which decision-makers
can rely on the results of studies external to their
institutional setting in making or revising formulary
decisions.
Conclusion
This CEA uses electronic medical records to assemble
patient-level data on real-world clinical characteristics
and prescribing practices. Compared to a focus on the
full sample population, couching the ICER within
clinically recognizable patient subgroups can help
identify a minimal set of CFU under which the utiliza-
tion of a new, expensive drug may actually be cost-
saving. CEAs that seek to identify practical and
potentially cost-saving CFU should become an integral
part of the formulary process.
Source of ﬁnancial support: The PhRMA Foundation pro-
vided funding for the study. The results were presented in
October 2006 at the International Society for Pharmacoeco-
nomics and Outcomes Research 9th Annual European Con-
gress in Copenhagen, Denmark.
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